Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 9/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248355 | 0.91 | HDAC4 (0.37) | HDAC4MEN1KMT2APGRNPC1 | |
| SCHEMBL889459 | 0.90 | HDAC4 (0.35) | HDAC4MEN1KMT2APGRNPC1 | |
| Laquinimod SCHEMBL889486 | 0.89 | MEN1 (0.46) | HDAC4MEN1KMT2APGRNPC1 | |
| Laquinimod SCHEMBL889435 | 0.89 | HDAC4 (0.39) | HDAC4MEN1KMT2APGRNPC1 | |
| SCHEMBL16248354 | 0.88 | HDAC4 (0.41) | HDAC4MEN1KMT2APGRNPC1 | |
| SCHEMBL889412 | 0.86 | KMT2A (0.40) | HDAC4MEN1KMT2APGRNPC1 | |
| Laquinimod SCHEMBL12009986 | 0.84 | MEN1 (0.40) | HDAC4MEN1KMT2APGRNPC1 | |
| Laquinimod SCHEMBL889478 | 0.83 | MEN1 (0.47) | HDAC4MEN1KMT2APGRNPC1 | |
| Laquinimod SCHEMBL12010001 | 0.83 | MEN1 (0.41) | HDAC4MEN1KMT2APGRNPC1 | |
| SCHEMBL16248352 | 0.80 | HDAC4 (0.39) | HDAC4MEN1KMT2APGRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051723-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2014-02-20 | — | — | US | disclosed |
| US-8580819-B2 | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-11-12 | — | — | US | disclosed |
| US-20120010238-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051723-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | HDHD5, DDAH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HDAC4 445/4885MEN1 1098/4885KMT2A 209/4885 |
| US-20120010238-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | HDHD5, DDAH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HDAC4 445/4885MEN1 1098/4885KMT2A 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.